NephroGenex welcomes queries from qualified news outlets and pharmaceutical sources. To speak with a representative of Nephrogenex, email to: [email protected]
Pressroom
-
- NephroGenex Announces the Successful Completion of PYR-210
- NephroGenex Reaches Agreement with the FDA on a New Pyridorin Subpart H Phase 3 Program for Pyridorin™
- NephroGenex Announces Full Enrollment in New PYR 210Pyridorin™ Clinical Trial
- NephroGenex Announces Initiation of New Pyridorin™ Clinical Trial
- Care Capital Leads Investment in NephroGenex
- NephroGenex Announces Appointment of Dr. Mark A. Klausner as Chief Medical Officer
- NephroGenex Licenses Pyridorin™ for Diabetic Nephropathy
- NephroGenex Licenses Advancement from Vanderbilt University Covering Pyridoxamine Therapy for Acute Renal Failure